The global initiative will be celebrated as International Children's Growth Awareness Day on
The #Together4Growth campaign communicates the importance of tracking and measuring a child's growth patterns and discussing any potential issues with a healthcare professional. It features a four-question Growth Quiz to help parents and caregivers identify common signs and symptoms of growth disorders and to find educational resources. During Growth Awareness Week, the public is encouraged to use #Together4Growth to share personal stories, tips and experiences about growth disorders on together4growth.com via their own social media channels.
'The signs and symptoms of growth disorders can often be overlooked in children or not recognized as being potentially linked to serious medical conditions and a child's overall endocrine health,' said
In
'Children who aren't growing properly may have early warning signs of a medical condition that is not just cosmetic. It's important and critical for parents to pay close attention to their child's growth, to be vigilant and not dismiss these signs as something he or she will outgrow,' said
About
Ascendis is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its platform technology to build a leading, fully integrated biopharma company, (ii) Ascendis' product pipeline and expansion into additional therapeutic areas, and (iii) Ascendis' expectations regarding its ability to utilize its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: unforeseen safety or efficacy results in its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs, selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis' ability to obtain additional funding, if needed, to support its business activities and the effects on its business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' prospectus supplement filed on
Ascendis,
Contact:
Tel: (415) 513-1284
Email: patti.bank@westwicke.com
(C) 2020 Electronic News Publishing, source